Skip to main content
Richards Afonja, MD, Oncology, Clifton, NJ

RichardsAAfonjaMD

Oncology Clifton, NJ

Physician

Are you Dr. Afonja?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 73 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    476 Colfax Ave
    Clifton, NJ 07013
    Phone+1 973-594-7977
    Fax+1 973-594-9983

Summary

  • Dr. Richards Afonja, MD is an oncologist in Clifton, New Jersey. He is currently licensed to practice medicine in New Jersey, Ohio, and Florida. He is affiliated with St. Joseph's University Medical Center and St. Mary's General Hospital.

Education & Training

  • Seton Hall University-Hackensack Meridian School of Medicine
    Seton Hall University-Hackensack Meridian School of MedicineFellowship, Medical Oncology, 1994 - 1997
  • Hackensack University Medical Center (Mountainside)
    Hackensack University Medical Center (Mountainside)Residency, Internal Medicine, 1992 - 1994
  • New York Medical College (Brooklyn-Queens)
    New York Medical College (Brooklyn-Queens)Internship, Internal Medicine, 1991 - 1992
  • University of Ibadan
    University of IbadanClass of 1987

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2022 - 2026
  • OH State Medical License
    OH State Medical License 2024 - 2026
  • TX State Medical License
    TX State Medical License 2023 - 2026
  • FL State Medical License
    FL State Medical License 2023 - 2025
  • NJ State Medical License
    NJ State Medical License 1994 - 2025

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Press Mentions

  • Immune Therapeutics, Inc., Announced the Completion of the Bridging Trial and Submission of Lodonal(TM)
    Immune Therapeutics, Inc., Announced the Completion of the Bridging Trial and Submission of Lodonal(TM)January 21st, 2016